- Home
- NRIX vs RWT Comparison
NRIX vs RWT Comparison
Compare NRIX & RWT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRIX
- RWT
- Stock Information
- Founded
- NRIX 2009
- RWT 1994
- Country
- NRIX United States
- RWT United States
- Employees
- NRIX N/A
- RWT N/A
- Industry
- NRIX Biotechnology: Pharmaceutical Preparations
- RWT Real Estate Investment Trusts
- Sector
- NRIX Health Care
- RWT Real Estate
- Exchange
- NRIX Nasdaq
- RWT Nasdaq
- Market Cap
- NRIX 728.6M
- RWT 756.1M
- IPO Year
- NRIX 2020
- RWT 1995
- Fundamental
- Price
- NRIX $8.97
- RWT $6.08
- Analyst Decision
- NRIX Strong Buy
- RWT Buy
- Analyst Count
- NRIX 14
- RWT 9
- Target Price
- NRIX $29.07
- RWT $7.36
- AVG Volume (30 Days)
- NRIX 847.4K
- RWT 823.2K
- Earning Date
- NRIX 10-10-2025
- RWT 10-29-2025
- Dividend Yield
- NRIX N/A
- RWT 11.94%
- EPS Growth
- NRIX N/A
- RWT N/A
- EPS
- NRIX N/A
- RWT N/A
- Revenue
- NRIX $88,381,000.00
- RWT $136,246,000.00
- Revenue This Year
- NRIX $74.59
- RWT N/A
- Revenue Next Year
- NRIX N/A
- RWT $25.80
- P/E Ratio
- NRIX N/A
- RWT N/A
- Revenue Growth
- NRIX 41.86
- RWT N/A
- 52 Week Low
- NRIX $8.18
- RWT $4.68
- 52 Week High
- NRIX $29.56
- RWT $8.15
- Technical
- Relative Strength Index (RSI)
- NRIX 42.73
- RWT 50.08
- Support Level
- NRIX $8.33
- RWT $6.13
- Resistance Level
- NRIX $10.13
- RWT $6.21
- Average True Range (ATR)
- NRIX 0.49
- RWT 0.14
- MACD
- NRIX -0.00
- RWT -0.02
- Stochastic Oscillator
- NRIX 35.56
- RWT 25.47
About NRIX Nurix Therapeutics Inc. Common stock
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.
About RWT Redwood Trust Inc.
Redwood Trust Inc is a real estate investment trust focused on different areas of housing credit. The company operates in three segments: Sequoia Mortgage Banking includes mortgage loan conduit that acquires residential consumer loans from third-party originators for sale to whole loan buyers and securitization; CoreVest Mortgage Banking segment includes consists of a platform that originates residential investor loans for securitization, sale, or transfer into Redwood Investments portfolio; and Redwood Investments segment consists of organic investments sourced through mortgage banking operations, including securities retained from Sequoia and CoreVest securitization activities. It derives maximum revenue from Redwood Investments segment.